Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?

Autor: Dorothée Boucherle, Yves Ranchoup, Marion Allouchery, Jérôme Long, Céline Villier, Nathalie Sturm, François Le Marc’Hadour, Marion Lepelley
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Receptor
ErbB-2
medicine.medical_treatment
Specialties of internal medicine
Ado-Trastuzumab Emtansine
Targeted therapy
chemistry.chemical_compound
0302 clinical medicine
Trastuzumab
Molecular Targeted Therapy
skin and connective tissue diseases
Biopsy
Needle
Carcinoma
Ductal
Breast
Liver Neoplasms
General Medicine
Middle Aged
Immunohistochemistry
Magnetic Resonance Imaging
RC581-951
030220 oncology & carcinogenesis
Female
Nodular regenerative hyperplasia
medicine.drug
Antibody-drug conjugate
medicine.drug_class
Breast Neoplasms
Monoclonal antibody
Risk Assessment
03 medical and health sciences
Breast cancer
Drug-induced disease
medicine
Humans
Maytansine
Trastuzumab emtansine
Hyperplasia
Hepatology
business.industry
medicine.disease
030104 developmental biology
chemistry
Withholding Treatment
Cancer cell
Cancer research
business
Follow-Up Studies
Zdroj: Annals of Hepatology, Vol 17, Iss 6, Pp 1067-1071 (2018)
ISSN: 1665-2681
Popis: Trastuzumab is a monoclonal antibody targeted against the Human Epidermal Growth Factor Receptor 2 (HER2) overexpressed in some breast cancer. This targeted therapy significantly improves the prognosis of these cancers. Recently an anti-HER2 antibodydrug conjugate was shaped in order to facilitate the targeted delivery of potent cytotoxic drug to cancer cells and to reduce resistance. This formulation, called trastuzumab emtansine (T-DM1), consists of the monoclonal antibody trastuzumab linked to a cytotoxic drug (a derivative of maytansine) via a chemical linker. Little is known about adverse reactions due to this new formulation. Herein we described the case of a woman suffering from a HER2-positive breast cancer, treated with trastuzumab for 30 months followed by T-DM1 monotherapy. After 12 months of T-DM1 treatment, a nodular regenerative hyperplasia confirmed by liver biopsy occurred. T-DM1 was stopped and medical imagery showed a resolution of the nodular regenerative hyperplasia. Unfortunately, hepatic metastasis progressed. Few cases of nodular regenerative hyperplasia induced by T-DM1 have been described so far. Further studies are needed to explore pathogenesis of nodular regenerative hyperplasia with this new antibody-drug conjugate treatment.
Databáze: OpenAIRE
Externí odkaz: